Chipscreen Biosciences Receives China IND Approval for NW001
Chipscreen Biosciences says China’s National Medical Products Administration approved an investigational new drug application for NW001, an antibody conjugate co-developed with Chengdu Chipscreen Newway Biosciences.
Story updates
01:30:51 PM UTC
SquawkNews
Shenzhen Chipscreen Biosciences obtained NMPA IND approval to start a Phase 1 trial of NW001, a PD-L1-targeted epigenetic immune-modulating antibody conjugate, in patients with advanced tumors.Material DetailsContext by AI AnalystThis is an early clinical milestone, expanding Chipscreen’s IO pipeli…